Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.

The Journal of pharmacology and experimental therapeutics - 1 Nov 2022

Franco Antonietta, Dang Xiawei, Zhang Lihong, Molinoff Perry B, Dorn Gerald W

Abstract excerpt

Mitofusin (MFN) 1 and MFN2 are dynamin GTPase family mitochondrial proteins that mediate mitochondrial fusion requiring MFN conformational shifts, formation of macromolecular complexes on and between mitochondria, and GTP hydrolysis. Damaging MFN2 mutations cause an untreatable, largely pediatric progressive peripheral neuropathy, Charcot-Marie-Tooth (CMT) disease type 2A. We used small molecule allosteric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Charcot-Marie-Tooth Disease
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Mitochondria

Share to Mitochondrial Proteins

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36507849
DOI: 10.1124/jpet.122.001332
PMCID: PMC9553116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.PMID 36507849Read ↗

Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.Semantic proximity Read ↗

Gene therapy-mediated overexpression of wild-type MFN2 improves Charcot-Marie-Tooth disease type 2ASemantic proximity Read ↗

Mitofusin 2 Dysfunction and Disease in Mice and MenSemantic proximity Read ↗

Structural insights of human mitofusin-2 into mitochondrial fusion and CMT2A onset.Semantic proximity Read ↗

Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro.Semantic proximity Read ↗

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives.Semantic proximity Read ↗

Mitofusin 2 mutation drives cell proliferation in Charcot-Marie-Tooth 2A fibroblasts.Semantic proximity Read ↗

Mitofusin gain and loss of function drive pathogenesis in Drosophila models of CMT2A neuropathy.Semantic proximity Read ↗

Charcot-Marie-Tooth type 2A in vivo models: Current updates.Semantic proximity Read ↗

Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults.Semantic proximity Read ↗

Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A.Semantic proximity Read ↗

Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.